Immunogenic composition
AssigneeGlaxosmithkline Biologicals SA
InventorsAgnese MARCELLI, Malte MEPPEN, Daniela STRANGES
Life of this patent
Estimating the term…
Abstract
The present invention relates to an improved immunogenic composition against N. meningitidis serogroups A, C, W135 and Y in solid form, and to a reconstituted vaccine against N. meningitidis serogroups A, B, C, W135, Y obtained by reconstitution with a liquid immunogenic composition of Men B antigens. Kits and methods for the prevention and treatment of meningococcal infection and disease with the immunogenic composition or the reconstituted vaccine are also provided.
Claims29
An immunogenic composition against N. meningitidis serogroups A, C, W135, and Y, comprising a composition of capsular polysaccharide antigens of the meningococcal serogroups A, C, W135, and Y conjugated to carrier protein(s) and one or more pharmaceutically acceptable excipients, wherein said composition is a lyophilized composition and said excipients comprise one or more bulking agents in amount ≤30 mg per unit dose of the composition of polysaccharide antigens in lyophilized form.
(canceled)
(canceled)
(canceled)
A pre-lyophilization solution comprising a composition of capsular polysaccharide antigens of the meningococcal serogroups A, C, W135, and Y conjugated to carrier protein(s), one or more pharmaceutically acceptable excipients, and an aqueous solution of a buffering agent, wherein said excipients comprise one or more bulking agents in a concentration ≤6% w/v, optionally ≤5% w/v with respect to the total volume of the solution.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.